OBJECTIVE: To observe the therapeutic efficacy of Yangxue Qingnao granules in the treatment of vertebrobasilar arterial insufficiency. METHODS: 95 patients with vertebrobasilar arterial insufficiency were randomly divided into treatment group (49 cases) and control group (46 cases). Control group was given conventional treatment and oral dose of Flunarizine hydrochlo-ride capsules(5 mg, qn) while treatment group was additionally given Yangxue Qingnao granules(4 g, tid) on the basis of control group for continuous 30 days. Clinical efficacy and the velocity change of vertebral basilar artery by transcranial doppler ultrasound before and after treatment were observed in 2 groups. Adverse drug reactions of patients were recorded during treatment. RESULTS: The total effective rate of treatment group was 95.92%, which was better than 84.78% of control group significantly (P< 0.05), the improvement of cerebral blood flow velocity in treatment group was better than in control group (P<0.01). No obvious side effect was found in treatment group during treatment. CONCLUSION: Yangxue Qingnao granules can improve dizziness and cerebral blood flow velocity without obvious side effect%目的:观察养血清脑颗粒对椎-基底动脉供血不足的治疗效果.方法:将95例椎-基底动脉供血不足的患者随机分为治疗组(49例)和对照组(46例).对照组给予基础治疗+盐酸氟桂利嗪胶囊5 mg,每晚顿服；治疗组在对照组的基础上加服养血清脑颗粒4 g,tid.2组均连续用药30 d.观察2组临床疗效及治疗前、后经颅多普勒椎-基底动脉血流速度的改变,并记录2组患者用药期间的不良反应.结果:治疗组症状改善总有效率为95.92％,显著优于对照组的84.78％ (P＜0.05)；治疗组脑血流速度亦较对照组显著改善(P＜0.01);2组在用药期间未见明显不良反应发生.结论:养血清脑颗粒能更好地改善椎-基底动脉供血不足引起的眩晕症状和脑血流速度.且安全性较好.
展开▼
